MorphoSys AG announced that Janssen-Cilag International NV (Janssen) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of Tremfya (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis in Europe.

Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody technology.

Dr. Simon Moroney, chief executive officer of MorphoSys AG, said: "We are very pleased that Janssen has received a positive opinion of the EMA's CHMP recommending to approve Tremfya in Europe. Assuming approval by the European Commission, we expect this drug to provide a valuable treatment option for patients living with moderate to severe plaque psoriasis in Europe, after Janssen received US FDA approval for Tremfya for the same indication earlier this year."

MorphoSys is eligible to royalties on net sales based on the product sales of Janssen related to Tremfya.